Thrivent Financial For Lutherans decreased its stake in shares of Atrion Co. (NASDAQ:ATRI) by 24.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,841 shares of the medical instruments supplier’s stock after selling 2,251 shares during the period. Thrivent Financial For Lutherans owned approximately 0.37% of Atrion worth $4,314,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Atrion by 2.6% during the fourth quarter. BlackRock Inc. now owns 100,724 shares of the medical instruments supplier’s stock worth $63,516,000 after acquiring an additional 2,549 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Atrion by 4.0% during the third quarter. Neuberger Berman Group LLC now owns 86,185 shares of the medical instruments supplier’s stock worth $57,916,000 after acquiring an additional 3,291 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Atrion by 1.6% in the third quarter. Dimensional Fund Advisors LP now owns 64,290 shares of the medical instruments supplier’s stock valued at $43,203,000 after purchasing an additional 1,022 shares in the last quarter. Renaissance Technologies LLC grew its position in Atrion by 2.6% in the fourth quarter. Renaissance Technologies LLC now owns 59,700 shares of the medical instruments supplier’s stock valued at $37,647,000 after purchasing an additional 1,500 shares in the last quarter. Finally, State Street Corp grew its position in Atrion by 3.0% in the second quarter. State Street Corp now owns 31,790 shares of the medical instruments supplier’s stock valued at $20,446,000 after purchasing an additional 919 shares in the last quarter. 59.17% of the stock is owned by institutional investors.
Separately, BidaskClub downgraded shares of Atrion from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th.
Atrion Co. (NASDAQ ATRI) opened at $606.50 on Friday. The firm has a market cap of $1,124.48, a price-to-earnings ratio of 30.77 and a beta of 0.70. Atrion Co. has a 12-month low of $459.50 and a 12-month high of $694.00.
Atrion (NASDAQ:ATRI) last released its earnings results on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share for the quarter. The business had revenue of $34.02 million during the quarter. Atrion had a net margin of 24.96% and a return on equity of 19.53%.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Thursday, March 15th will be given a $1.20 dividend. This represents a $4.80 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Wednesday, March 14th. Atrion’s dividend payout ratio (DPR) is currently 24.35%.
TRADEMARK VIOLATION WARNING: This piece was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/17/thrivent-financial-for-lutherans-lowers-stake-in-atrion-co-atri.html.
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.